Clinical Trial Update: Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial of relacorilant with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: TERMINATED | Results posted: 2023-11-18